HSPA9 and neuroblastoma: The elucidation of the molecular mechanism involved in the formation of tripartite GRP75/RARα/RXRα complexes provides the basis for the development of a novel therapeutic strategy for NB that could be combined with other existing differentiating regimens to improve the overall outcomes of NB patients [50], [51].